

Meeting link and Q&A via Vevox

https://teams.microsoft.com/l/meetup-MS Team Link for join/19%3ameeting_YjFIYTcxM2ItNWVIZi00MGIzLTgzYWQtYzg4MTA2ZWIxMzc5% Attendees 40thread.v2/0?context=%7b%22Tid%22%3a%2263982aff-fb6c-4c22-973b-70e4acfb63e6%22%2c%22Oid%22%3a%22d50ce047-1614-41b7-9379cf569a14071f%22%7d Posting of Q&As via Login to https://vevox.app/ Session ID:149-402-623 Vevox Or scan the QR Code



Agenda









Economic Overview

Economic Overview





Economic Overview







Company Overview

Board of Directors



Ms. Lai Kuen Goh (Chairperson)



Ms. Erum Shakir Rahim (Chief Executive Officer)



Mr. Hasham Baber (Chief Financial Officer)



Ms. Maheen Rahman (Independent Director)



Mr. Muneer Kamal (Independent Director)



Mr. Mehmood Mandviwalla (Non-Executive Director)



Mr. Simon Foster (Non-Executive Director)

Ms. Hina Mir appointed as Company Secretary on June 11, 2024.



Our purpose

We unite science, technology and talent to get ahead of disease together

How we'll get Ahead Together Our culture and thriving GSK people

Ambitious for patients

We're investing in innovation and growth at pace to achieve health impact at scale

Accountable for impact

We set focused objectives with clear measures of success

Do the right thing

We act responsibly and aim to lead the way on issues that matter







Financial Outline

Key financial highlights

	Sep 30, 2024	Sep 30, 2023
Net sales	Rs. 43.6 b	Rs. 37.0 b
Gross profit	Rs. 9.5 b	Rs. 2.6 b
Gross margin	21.9%	7.1%
Profit / (loss) after tax	Rs. 3.6 b	Rs. (0.4 b)
Earning per share	Rs. 11.25	Rs. (1.23)



Key Financial Ratios

Ratios	Sep 30, 2024	Sep 30, 2023
Return on equity	14.2%	-1.9%
Current Ratio	1.68	1.58
Inventory days	125	103
Receivable days	4	8
Payable days	66	46





Questions & Answers